AI assistant
SpyGlass Pharma, Inc. — Director's Dealing 2026
Feb 11, 2026
51541_dirs_2026-02-11_1f77b75e-ed5d-4a28-9c6e-1d490dc0500d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SpyGlass Pharma, Inc. (SGP)
CIK: 0001778922
Period of Report: 2026-02-09
Reporting Person: SANDELL SCOTT D (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-09 | Common Stock | C | 1619240 | — | Acquired | 1619240 | Indirect |
| 2026-02-09 | Common Stock | C | 1370168 | — | Acquired | 2989408 | Indirect |
| 2026-02-09 | Common Stock | C | 1370168 | — | Acquired | 4359576 | Indirect |
| 2026-02-09 | Common Stock | C | 737962 | — | Acquired | 5097538 | Indirect |
| 2026-02-09 | Common Stock | P | 937500 | $16.00 | Acquired | 6035038 | Indirect |
| 2026-02-09 | Common Stock | C | 954990 | — | Acquired | 954990 | Indirect |
| 2026-02-09 | Common Stock | C | 402273 | — | Acquired | 1357263 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-02-09 | Series B Preferred Stock | $ | C | 1619240 | Disposed | Common Stock (1619240) | Indirect | |
| 2026-02-09 | Series C-1 Preferred Stock | $ | C | 1370168 | Disposed | Common Stock (1370168) | Indirect | |
| 2026-02-09 | Series C-2 Preferred Stock | $ | C | 1370168 | Disposed | Common Stock (1370168) | Indirect | |
| 2026-02-09 | Series D Preferred Stock | $ | C | 737962 | Disposed | Common Stock (737962) | Indirect | |
| 2026-02-09 | Series A Preferred Stock | $ | C | 954990 | Disposed | Common Stock (954990) | Indirect | |
| 2026-02-09 | Series B Preferred Stock | $ | C | 402273 | Disposed | Common Stock (402273) | Indirect |
Footnotes
F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.
F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.
F3: The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.